Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Stifel still bullish on Momenta despite overhang, controversies

Stifel analyst Derek Archila maintained a Buy rating on Momenta and lowered his price target on shares to $39 from $40 after the company's Q3 earnings report. Archila said the earnings were a "non-event" and that he remains bullish in his long-term thesis on Momenta as he is optimistic about the company's M281 program, despite a near-term financial overhang and controversy surrounding M281's safety profile -- which the analyst has previously stated he is not overly concerned with.

Read more at:
https://thefly.com/landingPageNews.php?id=2819766

How in the world does this clown quantify $40 to $39....LOLOL